The DPP-4 inhibitors were as well-examined when added to on-going sulfonylurea in subjects with type 2 diabetes in 24–26 week placebo-controlled studies with a total number of 3,282 subjects [Table 2; (78–82)]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.